NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business earned $0.56 million during the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 analysts have issued 1 year target prices for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $13.83 in the next year. This suggests a possible upside of 62.6% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

News stories about SYRS stock have trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 15th total of 1,800,000 shares. Based on an average daily volume of 470,100 shares, the short-interest ratio is presently 5.0 days. Approximately 7.6% of the shares of the stock are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV), Endo International (ENDP), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Endonovo Therapeutics (ENDV), Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), Athenex (ATNX), ZEALAND PHARMA/S (ZEAL), Enanta Pharmaceuticals (ENTA), NextCure (NXTC) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), TherapeuticsMD (TXMD), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD) and ImmunoGen (IMGN).

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $8.51.

Syros Pharmaceuticals has a market capitalization of $360.95 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]